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 In 1965, Ferreira first reported on the 
venom of a viper ( Bothrops jararaca ) con-
taining a factor that potentiated the  in vivo 
and  in vitro actions of bradykinin. 1 He 
referred to this factor as  ‘ bradykinin-poten-
tiating factor, ’ or Bpf. A few years later, 
he joined Vane ’ s laboratory, in the United 
Kingdom, as a postdoc, carrying a vial of 
Bpf in his pocket. 2 Th ere, additional exper-
iments were conducted, and Bpf was found 
to be a potent inhibitor of the angio tensin-
converting enzyme (ACE). At that time, 
however, the role of the renin – angio tensin –
 aldosterone system (RAAS) as a major 
regulator of blood pressure was not yet well 
established. Bpf was then the starting point 
for the development of an entirely new class 
of antihypertensive agents. In 1981, aft er 
many years of research on drug develop-
ment, captopril, the fi rst ACE inhibitor, was 
approved by the US Food and Drug 
Administration. Th is was followed by the 
development of many other ACE inhibitors 
as well as agents acting on diff erent steps of 
the RAAS ( Figure 1 ). Since then, agents 
acting on the RAAS have been used to treat 
millions of patients with hypertension and 
cardiovascular disease. Studies in diabetes 
suggest that RAAS inhibitors might be 
especially benefi cial by delaying the onset 
of diabetic nephropathy. 
 Diabetes remains the main single cause of 
end-stage renal disease (ESRD) in the United 
States, responsible for nearly half of all new 
cases. 3 Although RAAS inhibitors were 
introduced several decades ago, and their 
use has been recommended by multiple 
guidelines, 4,5 epidemiological data showing 
a reduction in ESRD rates that can be attri b-
uted to the particular use of these agents in 
the early stages of disease are still lacking. 
 Hirst  et al. 6 (this issue) report on the com-
bined results of randomized clinical trials 
assessing the effects of RAAS inhibitors 
on urinary albumin excretion levels 
in patients with diabetes. Aft er extensive 
data analyses, the authors concluded that 
treatment with RAAS inhibitors reduced 
urinary albumin excretion in type 1 
diabetic patients with microalbuminuria, 
but not in those with normoalbuminuria. In 
contrast, these agents reduced urinary albu-
min excretion in both normoalbuminuric 
and microalbuminuric patients with type 2 
diabetes. However, it remains unanswered 
whether, as compared with other antihyper-
tensive agents, agents that block the RAAS 
early in the disease process (before overt 
proteinuria is present) reduce the 
incidence of ESRD. Moreover, in many 
of these studies, patients were classifi ed as 
normoalbuminuric, microalbuminuric, or 
macroalbuminuric / proteinuric on the basis 
of a single urine sample; no data on urinary 
albumin levels aft er washout were available; 
and patients randomized to RAAS inhibi-
tors oft en had lower blood pressure levels 
at baseline and / or during the study period 
than those randomized to placebo or other 
antihypertensive agents. 
 Importantly, reductions in albumin 
excretion rate (AER) with the use of 
RAAS-blocking agents are oft en transient, 
and may completely vanish soon aft er dis-
continuation of many years of therapy. 
Th us, in microalbuminuric type 1 diabetic 
patients, the reduction in AER observed 
aft er 8 years of RAAS blockade completely 
disappeared aft er 2 months ’ washout. 7 In 
this study, 7 there was no benefi t in terms 
of the rate of decline of glomerular fi ltra-
tion rate with the ACE inhibitor therapy. 
Perhaps even more striking are the results 
of the Renin Angiotensin System Study, 8 
showing an increased risk of microalbu-
minuria in initially normoalbuminuric 
normotensive type 1 diabetic patients 
randomized to losartan compared with 
those randomized to enalapril or placebo. 
This was associated with worsening of 
glomerular structural lesions. Similar to 
the observations in type 1 diabetes, the 
reduction in AER observed among micro-
albuminuric type 2 diabetic patients 
treated with 150  mg irbesartan for 2 years 
was no longer signifi cant aft er a 1-month 
washout, while 40 % of the AER benefi t 
observed during therapy with 300  mg 
irbesartan was lost over the washout 
period. 9 Unfortunately, data aft er a longer 
washout are not available. Remarkably, a 
 post hoc analysis of these data suggested 
that the degree of AER reduction within 
the fi rst 6 months of therapy was inversely 
associated with the rate of decline of 
glomerular filtration rate during the 
2 years of study. 10 
 Because microalbuminuria is not a pre-
cise predictor of proteinuria or ESRD in 
diabetes, 11 its use as a surrogate end point 
might be misleading. Ideally, progression to 
hard end points should be assessed. Assum-
ing that reductions in AER within the nor-
moalbuminuric and microalbuminuric 
ranges are of clinical relevance, it would 
be important to determine whether or 
not RAAS inhibitors provide additional 
 Viper venom for diabetic 
nephropathy 
 M. Luiza  Caramori 1 
 Diabetic nephropathy is the leading cause of end-stage renal disease 
in the United States. Renin – angiotensin – aldosterone system (RAAS) 
blockers are thought to have a specific renoprotective effect in diabetes. 
Hirst  et al. report the results of randomized clinical trials assessing the 
effects of RAAS inhibitors on urinary albumin excretion levels in 
diabetic patients. Although reductions in urinary albumin excretion 
were observed, whether RAAS inhibitors offer additional protection 
over other antihypertensive agents is unclear. 
 Kidney International (2012)  81, 615 – 616.  doi: 10.1038/ki.2011.460 
 1 Department of Medicine and Pediatrics, University 
of Minnesota ,  Minneapolis ,  Minnesota ,  USA 
 Correspondence: M. Luiza Caramori, Department 
of Medicine and Pediatrics, University of Minnesota, 
420 Delaware Street SE, Mayo Mail Code 101, 
Minneapolis, Minnesota 55455, USA. 
E-mail:  caram001@umn.edu 
commentar y
616   Kidney International (2012) 81 
renoprotection as compared with other anti-
hypertensive agents when the same blood 
pressure levels, both at baseline and during 
the follow-up period, are achieved. The 
claim that the benefi t of RAAS blockade is 
specifi c and independent of blood pressure 
control cannot be made based on statistical 
adjustment for blood pressure diff erences 
between groups, especially when lower 
blood pressure levels are present in patients 
receiving RAAS-blocking agents. Th e favor-
able impact of RAAS inhibitors on blood 
pressure levels is well known, and small 
reductions in blood pressure levels, even 
within the normal range, may have a signi-
fi cant impact on urinary albumin levels. 
 Hirst  et al. 6 suggest that monitoring for 
diabetic nephropathy in patients with type 
2 diabetes could, perhaps, be replaced by 
routine treatment with RAAS inhibitors. 
However, before such a recommendation 
can be made, RAAS inhibitors must be 
proven eff ective in the earlier stages of dis-
ease, so that viper ’ s venom can be accepted 
as the Holy Grail of diabetic nephropathy. 
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 Figure 1  |  Renin – angiotensin – aldosterone system. The renin – angiotensin – aldosterone system 
can be interrupted at different steps. Renin inhibitors inhibit the conversion of angiotensinogen 
into angiotensin I. Inhibitors of angiotensin-converting enzyme (ACE inhibitors) reduce the 
formation of the more potent angiotensin II, while angiotensin II receptor antagonists, also known 
as angiotensin receptor blockers (ARBs) or AT 1 -receptor antagonists, can prevent angiotensin II 
from acting on angiotensin receptors (AT). ACE cleaves a number of other peptides, including 
bradykinin, and this function is also inhibited by ACE inhibitors. 
